Biotechnology in Thoughts from the Centre
- Select a blog category
By Li Xiaofeng, Manager, Monitor Deloitte, London and David Xie, Director, Monitor Deloitte, Shanghai
China has rapidly become one of the larges biopharmaceuticals (biopharma) and medical products markets in the world and is projected to reach $145-175 billion in sales by 2022 (representing a compound annual growth rate of more than 5.5 percent from 2017).1 Profound changes, particularly in relation to shortening the time taken to obtain regulatory approval and widening market access, are making China a more attractive market for biopharma companies to launch innovative medical products. Indeed, since 2017, China has approved record numbers of innovative foreign drugs.2,3 These approvals follow a series of policy moves to provide public funding to enable China’s 1.4 billion population to access new, lifesaving drugs, especially cancer therapies. However many drug makers have had to slash prices so that government will cover the costs of some of the advanced treatments.4
My Take: Highlights from the 2018 FT Conference panel discussion on the potential for a successful life sciences economy in the UK
By John Haughey, Deloitte Industry Leader, Life Sciences & Health Care
Earlier this month I had the pleasure of chairing a panel of life science experts at the Global Financial Times Pharmaceutical and Biotechnology conference.1 The conference brought together some of our industry’s leading minds to discuss the commercial conundrums of disease prevention, the transformational impact of advanced gene and cell therapies and the hope and hype of patient-centricity. The discussion topic for my panel was - ‘Big Bang? Industrial Strategy - Creating a Successful Life Sciences Economy’, and was focused on the UK’s Industrial Strategy and in particular the UK’s sector deal for life sciences.2 In this week’s blog I wanted to share some of my key takeaways from our animated and insightful discussion.
By Karen Taylor, Director, Centre for Health Solutions
Following our 2014 and 2017 Life Science and Health Care Predictions reports, ‘A bold future?’ and ‘The future awakens’, this week we launched our third predictions report, A bold future for Life Sciences Regulation: Predictions 2025. This year’s report presents an unashamedly optimistic view on what Life Sciences regulation might look like in 2025 if both life science companies and regulators were to work more collaboratively, embrace disruptive technologies, and acquire new skills and talent. We argue that this would improve not only the productivity of the regulators and industry but also provide patients with access to the latest medical innovation much sooner. We also imagine through a series of ‘portraits’ how a regulator, company and patient might behave in 2025. This week’s blog provides an overview of the four predictions presented in our future of regulation report and examples of the evidence today that enable us to predict a bold future for life sciences regulation in 2025.
by Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP
This week’s blog by Greg Reh, Deloitte’s Global Life Sciences Leader first featured on the US Center for Health Solutions blog, A view from the Center.i In it Greg explores how emerging technologies can improve enrolment in, remove barriers of participation and increase drug adherence in pharma clinical trials.
by Dr. Mark Steedman, Research Manager, Centre for Health Solutions
Our recent report The future awakens: Life sciences and health care predictions 2022, uses evidence from today to predict what the world will look like in the year 2022. One of our predictions, ‘The future of medicine is here and now,’ explores how exponential advances in life-extending and precision therapies will improve patient outcomes. Much of the evidence informing this prediction is derived from advances in areas such as genomics, precision medicine and new cancer treatments, including CAR-T cell therapies. However, advances in other scientific areas, such as tissue engineering, are also gaining traction. This week’s blog explores developments in tissue engineering as a whole and zeros in on an exciting new development in retinal tissue engineering.
In December 2015 we launched our sixth annual report on ‘Measuring the return from pharmaceutical innovation’. Our research highlights the difficulties that the largest pharmaceutical companies face in delivering sustainable returns on their late stage R&D pipelines. Indeed, while the cost to develop an asset has increased by a third since we started our analysis six years ago, forecast average peak sales has declined by half. Additionally, our measure of forecast R&D return on investment (RoI) has also shown a significant downward trend, with the average across the 12 companies declining from over ten per cent in 2010 to just over four per cent in 2015.
You may have seen the headlines this week that pharma R&D returns are at their lowest level for at least 5 years. This comes from our 6th ‘Measuring the returns from pharmaceutical R&D’ report – an annual study which I have worked on for the last three years. I thought I’d take this opportunity to reflect on the origins of this report and its contribution to the debate on pharma R&D productivity.
On 29 September a report on the Genomics industry in the UK which we had prepared for the Office for Life Sciences was published. The report looks at the size, growth trends and industry composition of the market and provides insight into the potential drivers, challenges and opportunities facing the industry in the UK.i This blog highlights some of the key trends in human genomics, the development of the emergent UK market and the barriers that will need to be overcome if the benefits to the UK are to be fully realised.
This week the Center for Health Solutions is delighted to bring you a guest blog from one of our consultants in health care and life sciences:
The life science industry is facing significant challenges such as patent cliffs, pricing and market access restrictions as well as increasing regulatory pressure. These challenges fundamentally call into question traditional business models and, as a result, life science companies are increasingly looking to new and innovative ways to tackle these challenges
This week the Center for Health Solutions is delighted to bring you a guest blog from one of our regulatory compliance specialists in health care and life sciences: